ATE438630T1 - 5-sulfanyl-4h-1,2,4-triazolderivate und deren verwendung zur behandlung von somatostatine vermittelten krankheiten - Google Patents

5-sulfanyl-4h-1,2,4-triazolderivate und deren verwendung zur behandlung von somatostatine vermittelten krankheiten

Info

Publication number: ATE438630T1
Authority: AT; Austria
Prior art keywords: sulfanyl; mediated diseases; triazole derivatives; treating somatostatin; somatostatin
Prior art date: 2001-11-28

Application number

AT02796876T

Other languages

English (en)

Inventor

Contour Marie-Odile Galcera

Alban Sidhu

Pierre Roubert

Christophe Thurieau

Original Assignee

Ipsen Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-11-28

Filing date

2002-11-27

Publication date

2009-08-15

2001-11-28 Priority claimed from FR0115342A external-priority patent/FR2832710B1/fr

2002-11-27 Application filed by Ipsen Pharma filed Critical Ipsen Pharma

2009-08-15 Application granted granted Critical

2009-08-15 Publication of ATE438630T1 publication Critical patent/ATE438630T1/de

Links

AFBBKYQYNPNMAT-UHFFFAOYSA-N 1h-1,2,4-triazol-1-ium-3-thiolate Chemical class SC=1N=CNN=1 AFBBKYQYNPNMAT-UHFFFAOYSA-N 0.000 title 1
201000010099 disease Diseases 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/12—Oxygen or sulfur atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Physical Education & Sports Medicine (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Dermatology (AREA)
Obesity (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Child & Adolescent Psychology (AREA)
Hospice & Palliative Care (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)
Pulmonology (AREA)
Emergency Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Oncology (AREA)
Ophthalmology & Optometry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT02796876T 2001-11-28 2002-11-27 5-sulfanyl-4h-1,2,4-triazolderivate und deren verwendung zur behandlung von somatostatine vermittelten krankheiten ATE438630T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
FR0115342A FR2832710B1 (fr)	2001-11-28	2001-11-28	Derives de 5-sulfanyl-4h-1,2,4-triazoles et leur utilisation en tant que medicaments
FR0207697		2002-06-21
PCT/FR2002/004055 WO2003045926A1 (fr)	2001-11-28	2002-11-27	Derives de 5-sulfanyl-4h-1,2,4-triazoles et leur utilisation en tant que medicament

Publications (1)

Publication Number	Publication Date
ATE438630T1 true ATE438630T1 (de)	2009-08-15

Family

ID=26213278

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02796876T ATE438630T1 (de)	2001-11-28	2002-11-27	5-sulfanyl-4h-1,2,4-triazolderivate und deren verwendung zur behandlung von somatostatine vermittelten krankheiten

Country Status (22)

Country	Link
US (1)	US20050154039A1 (de)
EP (1)	EP1465880B1 (de)
JP (1)	JP2005513035A (de)
KR (1)	KR100961332B1 (de)
CN (1)	CN100462359C (de)
AR (1)	AR037465A1 (de)
AT (1)	ATE438630T1 (de)
AU (1)	AU2002361345B8 (de)
BR (1)	BR0214553A (de)
CA (1)	CA2468184A1 (de)
CZ (1)	CZ2004760A3 (de)
DE (1)	DE60233265D1 (de)
ES (1)	ES2330927T3 (de)
HU (1)	HUP0402489A3 (de)
MX (1)	MXPA04005099A (de)
MY (1)	MY133406A (de)
NO (1)	NO20042635L (de)
NZ (1)	NZ533397A (de)
PL (1)	PL370140A1 (de)
RU (1)	RU2367655C2 (de)
TW (1)	TWI283670B (de)
WO (1)	WO2003045926A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI252847B (en) *	2001-07-10	2006-04-11	Synta Pharmaceuticals Corp	Synthesis of taxol enhancers
TWI332943B (en) *	2001-07-10	2010-11-11	Synta Pharmaceuticals Corp	Taxol enhancer compounds
TWI297335B (en)	2001-07-10	2008-06-01	Synta Pharmaceuticals Corp	Taxol enhancer compounds
TWI330079B (en) *	2003-01-15	2010-09-11	Synta Pharmaceuticals Corp	Treatment for cancers
US7385084B2 (en) *	2004-06-23	2008-06-10	Synta Pharmaceutical Corp.	Bis(thio-hydrazide amide) salts for treatment of cancers
ES2594874T3 (es)	2004-11-18	2016-12-23	Synta Pharmaceuticals Corp.	Compuestos de triazol que modulan la actividad de HSP90
EP1877048A1 (de) *	2005-04-15	2008-01-16	Synta Pharmaceuticals Corporation	Kombinationskrebstherapie mit bis-(thiohydrazid)-amid-verbindungen
CA2618628C (en) *	2005-08-18	2014-11-18	Synta Pharmaceuticals Corp.	Triazole compounds that modulate hsp90 activity
CA2653222A1 (en)	2006-05-25	2007-12-06	Synta Pharmaceuticals Corp.	Triazole compounds that modulate hsp90 activity
US8034834B2 (en)	2006-05-25	2011-10-11	Synta Pharmaceuticals Corp.	Method for treating proliferative disorders with HSP90 inhibitors
US20080027047A1 (en) *	2006-05-25	2008-01-31	Weiwen Ying	Compounds that modulate HSP90 activity and methods for identifying same
KR20090045354A (ko)	2006-08-21	2009-05-07	신타 파마슈티칼스 코프.	증식성 장애를 치료하기 위한 화합물
WO2008027445A2 (en) *	2006-08-31	2008-03-06	Synta Pharmaceuticals Corp.	Combination with bis(thiohydrazide amides) for treating cancer
WO2008144268A1 (en) *	2007-05-15	2008-11-27	Boehringer Ingelheim International Gmbh	Urotensin ii receptor antagonists
KR100980328B1 (ko) *	2007-12-14	2010-09-06	한국생명공학연구원	단백질 포스파타제의 활성을 억제하는트리아졸릴-티오-에타논 유도체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 암 예방 및 치료용조성물
WO2009119534A1 (ja)	2008-03-26	2009-10-01	第一三共株式会社	新規テトラヒドロイソキノリン誘導体
CN101684103B (zh) *	2008-09-22	2011-04-06	天津药物研究院	1,2,4-三唑结构的化合物、其制备方法和用途
JP2012517479A (ja) *	2009-02-12	2012-08-02	エグゼリクシス，インコーポレイテッド	糖尿病および肥満の処置においてｔｇｒ５アゴニストとして使用するためのトリアゾールおよびイミダゾール誘導体
US9205086B2 (en)	2010-04-19	2015-12-08	Synta Pharmaceuticals Corp.	Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor
AU2012332424A1 (en)	2011-11-02	2014-06-05	Synta Pharmaceuticals Corp.	Combination therapy of Hsp90 inhibitors with platinum-containing agents
WO2013067162A1 (en)	2011-11-02	2013-05-10	Synta Pharmaceuticals Corp.	Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
WO2013074594A1 (en)	2011-11-14	2013-05-23	Synta Pharmaceuticals Corp.	Combination therapy of hsp90 inhibitors with braf inhibitors
US9598395B2 (en)	2012-03-23	2017-03-21	The Regents Of The University Of California	Premature-termination-codons readthrough compounds
CN103755652B (zh) *	2013-12-20	2015-08-05	陕西理工学院	一种磺酰胺类化合物及其应用
CN104370844A (zh) *	2014-10-29	2015-02-25	广西师范大学	3-硫酮-5-巯基甲基-1,2,4-三唑的合成方法
CN106831529A (zh) *	2016-12-11	2017-06-13	湖南华腾制药有限公司	一种三氟甲基吲哚衍生物的制备方法
MX2019009419A (es)	2017-02-08	2019-10-02	Ono Pharmaceutical Co	Compuesto que tiene actividad agonista del receptor de somatostatina y uso farmaceutico del mismo.
US11912687B2 (en)	2017-05-12	2024-02-27	Board of Trustees of the Southern Illinois University	3,4,5-trisubstituted-1,2,4-triazoles and 3,4,5-trisubstituted-3-thio-1,2,4-triazoles and uses thereof
WO2018209267A2 (en) *	2017-05-12	2018-11-15	Board Of Trustees Of The Southern Illinois University On Behalf Of Southern Illinois University Edwardsville	3,4,5-trisubstituted-1,2,4-triazoles and 3,4,5-trisubstituted-3-thio-1,2,4-triazoles and uses thereof
CN111875583B (zh) *	2017-10-17	2021-06-15	中国科学院上海药物研究所	三氮唑衍生物及其制备方法和用途
CN115504923B (zh) *	2021-06-22	2026-06-26	山东新时代药业有限公司	一种7-乙基色醇的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0409332A3 (en) *	1989-07-19	1991-08-07	Merck & Co. Inc.	Substituted triazoles as angiotensin ii antagonists
US5177095A (en) *	1990-02-13	1993-01-05	Merck & Co., Inc.	Triazole angiotensin II antagonists incorporating a substituted benzyl element
GB2263635A (en) *	1992-01-28	1993-08-04	Merck & Co Inc	Substitiuted triazoles as neurotensin antagonists
WO1995013268A1 (en) *	1993-11-12	1995-05-18	Gyógyszerkutató Intézet Kft.	Ulcer-inhibiting triazole derivatives, pharmaceutical compositions containing them and process for preparing same
DE4425144A1 (de) *	1994-07-15	1996-01-18	Basf Ag	Triazolverbindungen und deren Verwendung
US6080772A (en) *	1995-06-07	2000-06-27	Sugen, Inc.	Thiazole compounds and methods of modulating signal transduction
DE19600934A1 (de) *	1996-01-12	1997-07-17	Basf Ag	Substituierte Aza- und Diazacycloheptan- und Cyclooctanverbindungen und deren Verwendung
EP1007042A4 (de) *	1997-06-13	2001-07-04	Sugen Inc	Neue heterozyklische verbindungen zur modulation der protein-tyrosin-enzym-verwandten zellulären signaltransduktion
HUP0202648A3 (en) *	1998-06-12	2003-02-28	Sod Conseils Rech Applic	Imidazolyl derivatives, pharmaceutical compositions containing them and their use
FR2796945B1 (fr) *	1999-07-30	2002-06-28	Sod Conseils Rech Applic	Nouveaux derives d'hydantoines, de thiohydantoines, de pyrimidinediones et de thioxopyrimidinones, leurs procedes de preparation et leur application a titre de medicaments
FR2802206B1 (fr) *	1999-12-14	2005-04-22	Sod Conseils Rech Applic	Derives de 4-aminopiperidine et leur utilisation en tant que medicament
HUP0302415A2 (hu) *	2000-05-19	2003-11-28	Merck Patent Gmbh	Triazolszármazékokat tartalmazó gyógyszerkészítmények és új triazolszármazékok

2002
- 2002-11-27 AU AU2002361345A patent/AU2002361345B8/en not_active Ceased
- 2002-11-27 MY MYPI20024450A patent/MY133406A/en unknown
- 2002-11-27 NZ NZ533397A patent/NZ533397A/en not_active IP Right Cessation
- 2002-11-27 CA CA002468184A patent/CA2468184A1/fr not_active Abandoned
- 2002-11-27 MX MXPA04005099A patent/MXPA04005099A/es active IP Right Grant
- 2002-11-27 KR KR1020047008002A patent/KR100961332B1/ko not_active Expired - Fee Related
- 2002-11-27 CZ CZ2004760A patent/CZ2004760A3/cs unknown
- 2002-11-27 TW TW091134432A patent/TWI283670B/zh active
- 2002-11-27 PL PL02370140A patent/PL370140A1/xx not_active Application Discontinuation
- 2002-11-27 BR BR0214553-7A patent/BR0214553A/pt not_active IP Right Cessation
- 2002-11-27 DE DE60233265T patent/DE60233265D1/de not_active Expired - Lifetime
- 2002-11-27 CN CNB028276248A patent/CN100462359C/zh not_active Expired - Fee Related
- 2002-11-27 HU HU0402489A patent/HUP0402489A3/hu unknown
- 2002-11-27 JP JP2003547378A patent/JP2005513035A/ja active Pending
- 2002-11-27 US US10/496,820 patent/US20050154039A1/en not_active Abandoned
- 2002-11-27 WO PCT/FR2002/004055 patent/WO2003045926A1/fr not_active Ceased
- 2002-11-27 RU RU2004119406/04A patent/RU2367655C2/ru not_active IP Right Cessation
- 2002-11-27 AT AT02796876T patent/ATE438630T1/de not_active IP Right Cessation
- 2002-11-27 ES ES02796876T patent/ES2330927T3/es not_active Expired - Lifetime
- 2002-11-27 EP EP02796876A patent/EP1465880B1/de not_active Expired - Lifetime
- 2002-11-28 AR ARP020104601A patent/AR037465A1/es unknown
2004
- 2004-06-23 NO NO20042635A patent/NO20042635L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
HUP0402489A3 (en)	2009-09-28
EP1465880B1 (de)	2009-08-05
AR037465A1 (es)	2004-11-10
TW200300760A (en)	2003-06-16
KR100961332B1 (ko)	2010-06-04
NZ533397A (en)	2005-12-23
MXPA04005099A (es)	2004-08-19
AU2002361345B8 (en)	2008-06-26
EP1465880A1 (de)	2004-10-13
HK1070361A1 (zh)	2005-06-17
KR20040062969A (ko)	2004-07-09
CN100462359C (zh)	2009-02-18
TWI283670B (en)	2007-07-11
CN1617859A (zh)	2005-05-18
ES2330927T3 (es)	2009-12-17
DE60233265D1 (de)	2009-09-17
MY133406A (en)	2007-11-30
US20050154039A1 (en)	2005-07-14
JP2005513035A (ja)	2005-05-12
RU2367655C2 (ru)	2009-09-20
WO2003045926A1 (fr)	2003-06-05
NO20042635L (no)	2004-06-23
BR0214553A (pt)	2004-10-13
PL370140A1 (en)	2005-05-16
RU2004119406A (ru)	2005-05-10
HUP0402489A2 (hu)	2005-05-30
AU2002361345B2 (en)	2008-06-05
CZ2004760A3 (cs)	2005-01-12
AU2002361345A1 (en)	2003-06-10
CA2468184A1 (fr)	2003-06-05

Legal Events

Date	Code	Title	Description
2010-02-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE60233265D1 (de)	2009-09-17	5-sulfanyl-4h-1,2,4-triazolderivate und deren verwendung zur behandlung von somatostatine vermittelten krankheiten
DE60023128D1 (de)	2006-02-23	Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
DE69836752D1 (de)	2007-02-08	Prostaglandinagoniste und deren verwendung zur behandlung von knochenerkrankungen
ATE384699T1 (de)	2008-02-15	2,6-chinolinyl- und 2,6-naphthylderivate und deren verwendungen zur behandlung von vla-4 bezogenen krankheiten
DE60218493D1 (de)	2007-04-12	Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten
DE59603216D1 (de)	1999-11-04	Esterquats und ihre Verwendung zur Herstellung von oberflächenaktiven Mitteln, insbesondere zur Haar- und Körperpflege
ATE345792T1 (de)	2006-12-15	Verwendung von mit azetidinon substituierten derivaten bei der behandlung der alzheimer- krankheit
ATE204754T1 (de)	2001-09-15	Pharmazeutische zusammensetzung von metformin und fibrat, und ihre verwendung zur behandlung von hyperglykämie
DE60204548D1 (de)	2005-07-14	Mch antagonisten und deren verwendung zur behandlung von fettleibigkeit
DE60019556D1 (de)	2005-05-25	2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60019555D1 (de)	2005-05-25	2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60222671D1 (de)	2007-11-08	Thienopyrimidinedione und deren verwendung in der behandlung von autoimmunerkrankungen
DE60319865D1 (de)	2008-04-30	Substituierte amin-derivate und deren verwendung zur behandlung von angionese-bedingten erkrankungen
DE60140377D1 (de)	2009-12-17	Mch antagonisten und deren verwendung zur behandlung von fettleibigkeit
DE69720463D1 (de)	2003-05-08	Sulfonamid-derivate und ihre verwendung zur behandlung von zns-erkrankungen
FI952721A7 (fi)	1995-12-04	Aine maksa-sappi-sairauksien hoitamiseksi
ATE276245T1 (de)	2004-10-15	Indolderivate und deren verwendung zur behandlung von u.a. osteoporosis
ATE232865T1 (de)	2003-03-15	1,4-diazabicyclo(3.2.2)nonan-4-carboxylat und carboxamidderivate, ihre herstellung und therapeutische verwendung
DE69814431D1 (de)	2003-06-12	3,3-diarylpropylamine , ihre verwendung und herstellung
ATE534635T1 (de)	2011-12-15	N-pyrazinyl-phenylsulfonamide und deren verwendung zur behandlung von durch chemokine vermittelten krankheiten
DE69804659D1 (de)	2002-05-08	21-hydro-6,19-oxidoprogesterone (21oh-60p) und deren verwendung als arzneimittel zur behandlung von glukokortikoidüberschuss
DE69901177D1 (de)	2002-05-08	Platinkomplex, dessen herstellung und dessen therapeutische verwendung
NO20011409L (no)	2001-03-28	Farmasöytiske midler for behandling av Parkinsonssykdom, ADHD og mikroadenomer
DE69511579D1 (de)	1999-09-23	Biozide alkohole, ihre herstellung und ihre verwendung
ATE251170T1 (de)	2003-10-15	Titanverbindungen, deren herstellung und verwendung